CERo Therapeutics Holdings, Inc. Common Stock (CERO) — Cash Flow-to-Debt Ratio
CERo Therapeutics Holdings, Inc. Common Stock (CERO) has a Cash Flow-to-Debt Ratio of -0.24x as of March 2026, meaning its operating cash flow of $-2.76 Million could theoretically repay 0% of its total liabilities ($11.46 Million) in one year. Check CERo Therapeutics Holdings, Inc. Common (CERO) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
CERo Therapeutics Holdings, Inc. Common Stock Cash Flow-to-Debt Ratio (2021–2025)
Historical debt coverage capacity for CERo Therapeutics Holdings, Inc. Common Stock across 5 annual periods. Also explore CERo Therapeutics Holdings, Inc. Common asset portfolio for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for CERo Therapeutics Holdings, Inc. Common Stock (2021–2025)
Year-by-year debt coverage analysis for CERo Therapeutics Holdings, Inc. Common Stock. For market capitalisation and broader financial context, see CERo Therapeutics Holdings, Inc. Common market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.77x | $-16.08 Million | $9.09 Million | ▼ -147.6% |
| 2024 | -0.71x | $-5.79 Million | $8.10 Million | ▼ -482.4% |
| 2023 | -0.12x | $-5.79 Million | $47.18 Million | ▼ -348.2% |
| 2022 | -0.03x | $-1.09 Million | $39.90 Million | ▲ +63.7% |
| 2021 | -0.08x | $-697.11K | $9.25 Million | — |